---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence. Covers OPERA-01, OP-1250-001, OP-1250-003, OP-1250-002, and OPERA-02. 221 evidence topics quoted from 43 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 OPERA-01

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Trial objective

> “OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.1-2"></a>

###### Registered objective and comparators

> “This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.1-3"></a>

###### Main objectives in the EU trial authorization

> “1. To evaluate the safety of OP-1250 at the dose levels of 90 and 120 mg”
> “2. To compare PFS, based on a BIRC assessment, between arms of OP-1250 at the selected dose and SOC treatment”

Source: [EU CTIS 2023-505871-63-00](https://euclinicaltrials.eu/ctis-public/view/2023-505871-63-00)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2023-11-16” |
| Primary completion (estimated) | “2026-10-31” |
| Study completion (estimated) | “2028-02-29” |

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.2-2"></a>

###### Registration and start of enrollment

> “Clinical Trial Registration: Clinicaltrials.gov NCT06016738. Registered 17 August 2023.”
> “Enrollment began in November 2023.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.2-3"></a>

###### Countries with trial sites

> “Argentina Australia Austria Belgium Brazil Bulgaria Canada Czechia France Germany Hong Kong Hungary Italy Malaysia Mexico The Netherlands Poland Portugal Romania South Korea Spain Taiwan Thailand UK USA”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

<a id="topic-3.1.1.2-4"></a>

###### Enrollment completion and expected top-line results

> “In November 2023, we initiated OPERA-01, our pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC. We have completed enrollment and anticipate top-line results for this trial in the first quarter of 2027”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized, open-label, two-part design

> “The OPERA-01 study is a global phase III randomized, open-label, active-controlled study, consisting of two parts (Figure 2).”
> “In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-2"></a>

###### Part 1 dose selection

> “In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET”
> “The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-3"></a>

###### Prespecified criteria for selecting the Part 2 dose

> “The dose for Part 2 will be selected based on safety, efficacy, pharmacokinetics, and health-related patient-reported outcomes in Part 1.”

Source: [Pistilli et al. (2024)](https://olema.com/wp-content/uploads/2024/06/Olema_Final-ASCO2024_OPERA-01-TiP-Poster_6-2-24.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Regulatory alignment on the selected dose

> “today announced it has aligned with the U.S. Food and Drug Administration (FDA) to select 90 mg of palazestrant as the dose for Part 2 of the ongoing registrational Phase 3 OPERA-01 trial in second- and third-line estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-3.1.1.3-5"></a>

###### Stratified randomization

> “Participants (N = 510 overall and 470 in the primary analysis) are randomized to treatment arms using Interactive Response Technology, and randomization is stratified based on 1) the presence of ESR1-mut or absence of detectable ESR1 mutations (ESR1-mut-nd), assessed centrally on circulating tumor DNA (ctDNA) collected during screening period in line with NCCN Guidelines [16]; 2) prior lines of ET for advanced disease (1 vs 2); and 3) presence of visceral disease (yes vs no).”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-6"></a>

###### Independent data monitoring committee

> “An independent data monitoring committee (IDMC), comprising medical and statistical representatives not involved in the trial, is monitoring the safety, efficacy, and conduct of the trial.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.3-7"></a>

###### Two-part design as first presented

> “The study consists of two parts: a three-arm dose selection part (part 1), followed by assessment of the selected dose of palazestrant versus standard of care (part 2).”

Source: [Chan et al. (2023c)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OPERA-01-TiP_12-5-23.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Population

> “Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment. Participants must have progressed following treatment with the combination of ET and a CDK4/6i; one additional line of ET is allowed.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.4-2"></a>

###### Key inclusion criteria

> “Evaluable disease (measurable disease or bone-only disease).”
> “Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.”
> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Female participants can be pre-, peri- or postmenopausal.”
> “Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.4-3"></a>

###### Receptor status definitions

> “Laboratory-confirmed ER+, HER2– breast cancer (per ASCO-CAP guidelines)”
> “0 or 1+ by IHC for HER2 membrane protein”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.4-4"></a>

###### Key exclusion criteria

> “Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.”
> “Previously received chemotherapy in the advanced/metastatic setting.”
> “Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy.”
> “Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.4-5"></a>

###### Prior antibody-drug conjugates and washout periods

> “Prior chemotherapy (including ADC) in the advanced/metastatic setting”
> “Fulvestrant, <28 days prior”
> “ET, CDK4/6i, everolimus, tacrolimus, alpelisib, or PARP inhibitors, <14 days prior”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Palazestrant and comparator regimens

> “In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1. Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.5-2"></a>

###### Comparator doses and schedules

> “Fulvestrant 500 mg IM on day 1 of each 28-day cycle, with an additional dose on day 15 of cycle 1 (recommended for patients who had not previously received fulvestrant), anastrozole 1 mg (oral once daily), letrozole 2.5 mg (oral once daily), and exemestane 25 mg (oral once daily). GnRH agonist requested for premenopausal women and for men.”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

<a id="topic-3.1.1.5-3"></a>

###### Treatment cycles and duration

> “All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.5-4"></a>

###### Tablet formulation

> “In OPERA-01 pivotal Phase 3 trial, patients are receiving tablet formulation instead of the capsules utilized in current dataset”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-3.1.1.5-5"></a>

###### Rationale for the endocrine monotherapy control arm

> “The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy, supported by evidence demonstrating sustained endocrine sensitivity and responsiveness of ER+, HER2− breast cancer to fulvestrant, tamoxifen, or non-steroidal AIs ET, even after prior ET failures [16–18,45–51]. As a global study, the SOC control arm has been planned to account for regional variations in standard practices.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Progression-free Survival by Blinded Independent Central Review as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Dual primary endpoint

> “The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.6.1-2"></a>

###### Registered primary outcome measures

> “Dose-Selection Part: Incidence of adverse events”
> “Dose-Selection Part: Incidence of dose reduction”
> “Dose-Selection Part: Incidence of drug discontinuation”
> “To compare PFS, based on a Blinded Independent Review Committee (BIRC) assessment, between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1-mutation detected and ESR1-mutation not detected participants.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.6.1-3"></a>

###### Rationale for separate analyses by ESR1 mutation status

> “However, recent reports indicate that the clinical benefit in ER+, HER2– ABC may be limited to patients with ESR1-mutated (ESR1-mut) tumors, rather than the entire patient population: trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations [28,29].”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.6.1-4"></a>

###### Regulatory rationale for progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit. Its determination is not confounded by subsequent therapy.”
> “When the primary study endpoint is based on tumor measurements (e.g., PFS or ORR), tumor assessments generally should be verified by central reviewers blinded to study treatments (see Appendix) to ascertain lack of assessment bias.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-5"></a>

###### Secondary endpoints

> “Key secondary endpoints of overall survival (OS), defined as the time from randomization to the date of death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another subsequent anti-cancer therapy, will be assessed separately in participants with ESR1-mut and ESR1-mut-nd tumors.”
> “BICR-assessed PFS in the ITT population”
> “PROs (assessed using EQ-5D-5 L and EORTC QLQ-C30)”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.6.1-6"></a>

###### Tumor and safety assessments

> “Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.”
> “Tumor response and disease progression are assessed locally and centrally using body imaging by computed tomography (preferred) or magnetic resonance imaging. Baseline tumor imaging is performed during screening, within 28 days of randomization, and radiographic assessments are conducted periodically.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment

> “Approximately 510 participants are expected to be enrolled, including 470 for the primary analysis.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Estimated | “510” |

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned enrollment by part

> “In the dose-selection part of the trial, approximately 120 participants will be randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter, approximately 390 participants will be randomized to palazestrant at the selected dose or to the standard-of-care endocrine therapy.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants randomized in Part 1 and planned for the primary comparison

> “The study included the dose selection part where approximately 120 patients were randomized between 90 mg QD palazestrant, 120 mg QD palazestrant, or SOC ET.”
> “Out of 510 patients to be enrolled in total, 470 patients will be randomized between 90 mg QD palazestrant or SOC ET.”

Source: [Pistilli et al. (2025)](https://ir.olema.com/static-files/61ec4071-51a5-4a03-aadb-1d296ccd53cb)

<a id="topic-3.1.1.7.1-5"></a>

###### Planned participants per arm

| Part and arm | Planned participants |
| --- | --- |
| Total | “n = 510” |
| Part 1, each arm (palazestrant 90 mg, palazestrant 120 mg, standard-of-care endocrine therapy) | “n = 40” |
| Part 2, each arm (palazestrant 90 mg, standard-of-care endocrine therapy) | “n = 195 (total 235)” |

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-3.1.1.7.1-6"></a>

###### Enrollment completion

> “Completed enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with second or third-line estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC).”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Primary and key secondary analyses

> “Blinded independent committee review (BICR)-assessed PFS, locally assessed PFS, and overall survival (OS) will be analyzed separately in participants with ESR1-mut tumors and participants with ESR1-mut-nd tumors by Kaplan–Meier (KM) methods; median and 95% confidence intervals (CIs) will be reported. Significant differences between treatment groups will be analyzed using the stratified log-rank test, stratified by a number of prior lines of ET and presence or absence of visceral metastases. Cox regression models will be used to estimate hazard ratios and 95% CIs.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.7.2-2"></a>

###### Response endpoints

> “Other secondary endpoints – overall response rate (ORR), CBR, and duration of response (DoR) – will be analyzed using both BICR- and investigator-assessed response evaluations.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.7.2-3"></a>

###### Part 1 dose-selection analysis

> “In Part 1 of the study, the selected dose was based on analyses of safety, preliminary efficacy, PK/pharmacodynamic (PD) parameters, and other relevant clinical and laboratory data, and there was no formal statistical comparison.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

No efficacy or safety results from OPERA-01 have been reported; enrollment is complete, and top-line results are anticipated in the first quarter of 2027. The trial is open label, with PFS assessed by blinded independent central review as the dual primary endpoint. The 90 mg Part 2 dose was chosen from Part 1 data with no formal statistical comparison. The control arm is endocrine monotherapy (fulvestrant or an aromatase inhibitor), and fulvestrant was recommended to participants who had not previously received it. Eligibility excludes participants with prior chemotherapy in the advanced or metastatic setting, prior elacestrant, or symptomatic visceral disease, permits at most one additional line of endocrine therapy after the endocrine therapy and CDK4/6 inhibitor combination, and requires the most recent endocrine therapy to have lasted at least 6 months. Participants receive a tablet formulation, whereas the earlier monotherapy data were obtained with capsules. The trial design publication was funded by Olema Oncology, which was involved in the study design.

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm); [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/); [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738); [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-3.1.1.9-2"></a>

###### Open-label design

> “A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

<a id="topic-3.1.1.9-3"></a>

###### Fulvestrant recommended only for participants without prior fulvestrant

> “Fulvestrant was recommended to patients who have not previously received fulvestrant.”
> “The inclusion of AI monotherapy ensures consistency with guideline-supported treatment options across diverse clinical settings [16–18,49].”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-3.1.1.9-4"></a>

###### Sponsor role

> “This manuscript was funded by Olema Oncology. The funder was involved in the study design and collaborated with the authors on the preparation of this manuscript.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="heading-3.1.2"></a>

#### 3.1.2 OP-1250-001

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Study objectives

> “This study (NCT04505826) was an open-label, multicenter, phase 1/2 study designed to identify the maximum tolerated dose (MTD), establish the recommended phase 2 dose (RP2D), and investigate the safety, pharmacokinetics (PK), and antitumor activity of single-agent palazestrant in patients with previously treated ER+/HER2− advanced and metastatic breast cancer”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.1-2"></a>

###### Primary and secondary objectives

> “Primary objectives: Pharmacokinetics, safety, tolerability, RP2D”
> “Secondary objectives: ORR, CBR (CR + PR + SD ≥24 weeks)”
> “Objectives: Efficacy, safety and tolerability at RP2D”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study sites and enrollment period

> “The analysis presented here includes clinical and laboratory data from 146 patients recruited at 15 sites in the US and Australia between August 2020 and November 2022.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.2-2"></a>

###### Trial registration and data cutoff of the primary publication

> “ClinicalTrials.gov, NCT04505826. Registered August 6, 2020.”
> “at the time of data cutoff (July 7, 2023)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.2-3"></a>

###### Last participant enrolled

> “Last patient enrolled Nov 2022”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.2-4"></a>

###### Interim data cutoff: dose escalation

> “Data cut-off date for this analysis was October 1, 2021”
> “A total of 40 patients were treated between August 2020 and October 2021”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-3.1.2.2-5"></a>

###### Interim data cutoff: dose escalation and dose expansion

> “Data cut-off date for this analysis was 2 September 2022”

Source: [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Dose escalation and dose expansion phases

> “Phase 1 of the study comprised a dose-escalation phase (1a) to identify the MTD using a rolling 6 patient dose-escalation design with 7 dose levels. Two doses of palazestrant (60 mg/day and 120 mg/day) were selected for the dose-expansion phase (1b) to further characterize the safety, PK, and preliminary antitumor activity of treatment and to establish the RP2D.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-2"></a>

###### Phase 2 cohorts at the recommended phase 2 dose

> “Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D (120 mg/day) in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and central nervous system (CNS) metastases (exploratory cohort).”
> “The data presented here include patients from phase 1a/1b and the measurable disease and nonmeasurable evaluable disease cohorts from phase 2.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-3"></a>

###### Dose escalation rules

> “Dose escalation cohorts enrolled up to 6 patients at each level; each patient was enrolled in only 1 dose cohort.”
> “In the event of 1 of 3 patients experiencing a DLT at a given dose level, a total of 6 patients would be treated at that dose level, and dose escalation would proceed if no more than 1 DLT was observed after 1 cycle of treatment. In the event of 2 or more patients experiencing DLTs at a given dose level, dose escalation stopped, and this dose level was declared the maximally administered dose.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-4"></a>

###### Selection of two doses for dose expansion

> “Dose selection was based on the observation of confirmed PRs at both dose levels”
> “and PK data indicating that palazestrant steady-state plasma concentrations reached the predicted efficacy threshold based on estradiol-supplemented preclinical models for both doses”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-5"></a>

###### Dose expansion at two dose levels (dose escalation report)

> “Phase 1b dose expansion is ongoing in the targeted dose range at 2 dose levels and will inform selection of RP2D”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Disease and prior endocrine therapy (all phases)

> “Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer who had received at least 1 prior line of endocrine therapy for advanced or metastatic disease for at least 6 months continuously and had received no more than 2 lines of prior chemotherapy regimens for metastatic disease.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-2"></a>

###### Exclusion of primary endocrine resistance

> “Patients who had disease progression within the first 2 years from the start of adjuvant endocrine therapy were not eligible, since these patients were considered to have tumors with primary endocrine resistance.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-3"></a>

###### Performance status, disease evaluability, and permitted prior therapies

> “Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and had evaluable disease. Measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) was not a requirement for the dose escalation phase. Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-4"></a>

###### Additional criteria for phase 1b and phase 2

> “In phase 1b/2 of the study, eligible patients met the same key inclusion criteria defined in phase 1a and were also required to have measurable disease per RECIST v1.1, unless they were enrolled in the nonmeasurable disease cohort of patients with nonmeasurable but evaluable disease. In addition, patients must have received no more than 1 prior chemotherapy regimen for metastatic disease and have received at least 1 (but no more than 4) prior lines of endocrine therapy for advanced or metastatic disease.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-5"></a>

###### Exclusion criteria

> “Patients were excluded from all phases of the study if they had impaired cardiac function, cerebral vascular disease, or a recent thromboembolic event, an ongoing serious infection or gastrointestinal disorder that could affect absorption of study treatment, a clinically significant history of liver disease consistent with Child–Pugh class B or C, other comorbidities that could affect the patient’s ability to participate in the study, or any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers).”
> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Palazestrant regimen and dose levels

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose. The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-2"></a>

###### Treatment duration

> “Palazestrant treatment was continued until intolerable toxicity, disease progression, study/treatment withdrawal, or death.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-3"></a>

###### Ovarian function suppression and restricted concomitant medications

> “Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.”
> “proton pump inhibitors and most common antiemetic medications were not permitted”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-4"></a>

###### Selection of 120 mg/day as the recommended phase 2 dose

> “Greater clinical benefit at palazestrant 120 mg/day (46%) versus 60 mg/day (19%) led to selection of 120 mg/day as RP2D and study expansion dose.”
> “Furthermore, because patients stayed on this treatment longer, the CBR was numerically better, and the safety profile was similar to that of the 60 mg dose, this dose was further explored in phase 2 of the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-5"></a>

###### Anticipated dose range after dose escalation

> “60 mg to 120 mg was identified as the anticipated recommended phase 2 dose (RP2D) range”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Dose-limiting Toxicity as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Definition of the maximum tolerated dose and dose-limiting toxicities

> “The MTD was defined as the highest feasible dose in phase 1a in which fewer than 33% of patients (of at least 6 treated) experienced a treatment-related DLT during cycle 1. In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.6.1-2"></a>

###### Ocular toxicity as a dose-limiting toxicity

> “Grade ≥ 3 blurred vision or retinopathy”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="topic-3.1.2.6.1-3"></a>

###### Safety and pharmacokinetic assessments

> “Safety assessments included the monitoring of AEs, clinical laboratory parameters, electrocardiograms, and vital signs. AE severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).”
> “The assessment of palazestrant single- and multiple-dose PK parameters included the maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), average plasma concentration (Cavg), area under the concentration–time curve from 0–24 h (AUC0–24), effective half-life (t1/2), and time to maximum plasma concentration (Tmax).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.6.1-4"></a>

###### Efficacy end points: response, clinical benefit rate, and progression-free survival

> “Key efficacy end points included assessment of clinical response according to RECIST v1.1; the clinical benefit rate (CBR), defined as the proportion of patients who achieved a complete response (CR), achieved a partial response (PR), or had stable disease (SD) for at least 24 weeks; and progression-free survival (PFS), defined as the time from the date of the first dose to disease progression or death. Biomarker assessments included changes from baseline in circulating tumor DNA (e.g., ESR1 variants) and tumor tissue biomarkers (ERα and Ki67).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.6.1-5"></a>

###### Electrocardiogram analysis method

> “The Corrected QT interval according to Fridericia’s formula (QTcF) and heart rate (HR) from electrocardiogram (ECG) data analysis will be conducted based on methodology recommended in the ICH E14 guideline”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned sample size and precision

> “A sample size of approximately 30 patients per dose group in the phase 1b dose expansion cohorts was expected to provide an estimated precision of ± 19% for any binary event rate assessment. In phase 2, a sample size of approximately 50 patients treated at the RP2D was expected to provide an estimated precision of ± 15% for binary assessments.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants enrolled and analyzed

> “This study enrolled 146 patients.”
> “During the dose escalation phase of the study, 42 patients were treated with once-daily oral palazestrant at doses ranging from 30 to 300 mg”
> “Baseline demographics and characteristics for all patients treated at 60 mg/day or 120 mg/day (n = 116; including those from the dose-escalation phase) are presented in Table 1.”
> “Of the 116 patients treated in the 60-mg and 120-mg dose cohorts, 92 (79.3%) patients with measurable disease were evaluable for tumor response.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.1-3"></a>

###### Composition of the 120 mg population

> “Includes patients from phase 1 (dose escalation and dose expansion) and phase 2 at 120 mg, and 3 patients whose dose was increased from 60 to 120 mg early in treatment.”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

Additional sources: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Analysis populations in the primary publication

> “All DLT analyses (phase 1a) were performed in patients enrolled in the study during cycle 1 and who either received 75% of the planned palazestrant doses or experienced a DLT during cycle 1. All PK analyses were performed in patients who received at least 1 dose of palazestrant and had adequate postbaseline PK samples for characterization of PK parameters. All safety analyses were performed and PFS assessed in patients who received at least 1 dose of palazestrant. Clinical response (CR or PR) was assessed in patients who received at least 1 cycle of palazestrant, had measurable disease at baseline, and had at least 1 postbaseline tumor assessment. CBR was assessed in patients who received at least 1 cycle of palazestrant, had at least 1 postbaseline tumor assessment, and started their first dose at least 24 weeks before data cutoff. Patients who discontinued study treatment without radiographic progression within 24 weeks from the first dose were not included in the CBR analysis.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.2-2"></a>

###### Statistical methods

> “For CBR, estimates were accompanied by 2-sided 95% confidence intervals (95% CIs). For PFS, Kaplan–Meier analyses were used to determine medians, event-free rates, and 95% CIs.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.2-3"></a>

###### Analysis sets in the statistical analysis plan

> “The safety analysis set (SAF) will include all subjects who received at least 1 full or partial dose of OP-1250. Subjects will be analyzed according to the OP-1250 doses they actually received as a first dose.”
> “The full analysis set (FAS) includes all subjects who received at least 1 dose of OP-1250 and have at least 1 post-baseline tumor assessment.”
> “The efficacy analysis set (EFS) will include all subjects who received at least 1 cycle of OP-1250 and have at least 1 post-baseline tumor assessment.”
> “The CBR analysis set (CBRAS) will include subjects in EFS, who started their first dose 24 weeks before data cut off. Subjects who are on treatment for less than 24 weeks, without radiographic progression per RECIST 1.1 will be excluded.”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Treatment status and reasons for discontinuation at 60 or 120 mg/day

> “Among all patients treated with 60 or 120 mg/day palazestrant, 102/116 (87.9%) had discontinued treatment at the time of data cutoff (July 7, 2023) and 14 (12.1%) were ongoing. Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.1-2"></a>

###### Dose escalation disposition

> “Of 40 patients, 16 were still on treatment at the time of data cut-off, and 17 had discontinued OP-1250 due to progressive disease”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

Additional sources: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline characteristics at 60 and 120 mg/day

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Age, years; median (range) | “59.5 (30–81)” | “61.0 (32–85)” | “61.0 (30–85)” |
| Female, n (%) | “30 (100)” | “86 (100)” | “116 (100)” |
| White, n (%) | “23 (76.7)” | “70 (81.4)” | “93 (80.2)” |
| Black or African American, n (%) | “1 (3.3)” | “7 (8.1)” | “8 (6.9)” |
| Asian, n (%) | “1 (3.3)” | “3 (3.5)” | “4 (3.4)” |
| Race not reported or other, n (%) | “5 (16.7)” | “6 (7.0)” | “11 (9.5)” |
| Childbearing potential, n (%) | “0” | “7 (8.1)” | “7 (6.0)” |
| ECOG performance status 0, n (%) | “19 (63.3)” | “46 (53.5)” | “65 (56.0)” |
| ECOG performance status 1, n (%) | “11 (36.7)” | “40 (46.5)” | “51 (44.0)” |
| Measurable disease, n (%) | “29 (96.7)” | “69 (80.2)” | “98 (84.5)” |
| Visceral disease, n (%) | “24 (80.0)” | “61 (70.9)” | “85 (73.3)” |
| 1 prior line of therapy in advanced setting, n (%) | “9 (30)” | “21 (24.4)” | “30 (25.9)” |
| 2 prior lines of therapy in advanced setting, n (%) | “6 (20.0)” | “29 (33.7)” | “35 (30.2)” |
| 3 prior lines of therapy in advanced setting, n (%) | “6 (20.0)” | “19 (22.1)” | “25 (21.6)” |
| 4 prior lines of therapy in advanced setting, n (%) | “6 (20.0)” | “10 (11.6)” | “16 (13.8)” |
| 5 or more prior lines of therapy in advanced setting, n (%) | “3 (10.0)” | “7 (8.1)” | “10 (8.6)” |
| 1 prior line of endocrine therapy in advanced setting, n (%) | “12 (40.0)” | “30 (34.9)” | “42 (36.2)” |
| 2 prior lines of endocrine therapy in advanced setting, n (%) | “7 (23.3)” | “32 (37.2)” | “39 (33.6)” |
| 3 prior lines of endocrine therapy in advanced setting, n (%) | “7 (23.3)” | “15 (17.4)” | “22 (19.0)” |
| 4 prior lines of endocrine therapy in advanced setting, n (%) | “3 (10.0)” | “8 (9.3)” | “11 (9.5)” |
| 5 prior lines of endocrine therapy in advanced setting, n (%) | “1 (3.3)” | “1 (1.2)” | “2 (1.7)” |
| Prior CDK4/6 inhibitor, n (%) | “28 (93.3)” | “83 (96.5)” | “111 (95.7)” |
| Prior aromatase inhibitor, n (%) | “23 (76.7)” | “73 (84.9)” | “96 (82.8)” |
| Prior fulvestrant, n (%) | “19 (63.3)” | “57 (66.3)” | “76 (65.5)” |
| Prior chemotherapy, n (%) | “12 (40.0)” | “27 (31.4)” | “39 (33.6)” |
| ESR1 mutations (ctDNA) at baseline, n/N (%) | “15/21 (71.4)” | “36/75 (48.0)” | “51/96 (53.1)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.2-2"></a>

###### Prior treatment at 60 and 120 mg/day

> “Patients had a median age of 61 years, the majority had measurable or visceral disease (84.5% and 73.3%, respectively), 74.1% of patients received at least 2 prior lines of systemic therapy in the advanced setting (median 2; range, 1–8), approximately two-thirds (63.8%) received at least 2 prior lines of endocrine therapy in the advanced setting (median 2; range, 1–5), and all but 5 patients (95.7%) received prior CDK4/6 inhibitor therapy.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.2-3"></a>

###### Prior mTOR inhibitor therapy at 120 mg

> “42% of patients received ≥3 prior lines of systemic therapy for metastatic disease”
> “mTOR inhibitor 25 (29)”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.2-4"></a>

###### Dose escalation population

> “Thirty-eight patients were postmenopausal women, 1 patient was pre/perimenopausal, and 1 patient was male.”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Response and clinical benefit by dose level

| Endpoint | 60 mg/day | 120 mg/day |
| --- | --- | --- |
| Response-evaluable participants with measurable disease | “(n = 26)” | “66 response-evaluable patients treated with 120 mg/day palazestrant” |
| Confirmed partial responses | “2 confirmed PRs (cPRs; 7.7%)” | “3 confirmed PRs (4.5%)” |
| Unconfirmed partial responses | “1 unconfirmed PR (3.8%)” | “2 unconfirmed PRs (3.0%)” |
| All partial responses | “a total of 3 PRs (11.5%)” | “a total of 5 PRs (7.6%)” |
| Clinical benefit rate, all evaluable participants | “19.2% (95% CI, 6.6–39.4)” | “45.7% (95% CI, 33.7–58.1)” |
| Participants evaluable for clinical benefit rate | “(n = 26)” | “(n = 70)” |
| Clinical benefit rate, ESR1 mutation | “23.1% (95% CI, 5.0–53.8)” | “58.6% (95% CI, 38.9–76.5)” |
| Participants with ESR1 mutation evaluable for clinical benefit rate | “among the 13 patients with cancers with ESR1 mutations” | “(n = 29)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-2"></a>

###### Confirmed response after the data cutoff and tumor shrinkage at 120 mg/day

> “One additional patient treated at the RP2D had a cPR after the data cutoff date for a total of 4 confirmed PRs (6.0%).”
> “A reduction in tumor size (percentage change less than zero) was experienced by 25/64 (39.1%) patients treated at the R2PD, including 8/64 (12.5%) who experienced a > 30% reduction”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-3"></a>

###### Duration of treatment at 120 mg/day

> “Palazestrant treatment led to prolonged disease stabilization, with 32/86 (37.2%) of patients treated at 120 mg/day remaining on treatment for ≥ 6 months and 6 (7.0%) remaining on treatment for ≥ 1 year”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-4"></a>

###### Progression-free survival at 120 mg/day, overall and with ESR1 mutation

> “The median PFS for patients receiving 120 mg/day palazestrant was 4.8 months (95% CI, 3.5–7.1), with a 6-month PFS rate of 39%”
> “In patients with cancers with ESR1 mutations treated at the R2PD, the median PFS was 5.6 months (95% CI, 4.8-NE), and the 6-month PFS rate was 47%”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-5"></a>

###### Clinical benefit rate at 120 mg by subgroup (conference presentation)

> “All patients: 40% (32/81)”
> “Prior fulvestrant: 41% (22/54)”
> “ESR1 mutation: 52% (17/33)”
> “ESR1 wild-type: 32% (12/38)”
> “3 cPRs and 2 uPRs† in 66 response-evaluable patients”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.3-6"></a>

###### Second- or third-line subset at 120 mg (conference presentation)

| Population | Median PFS, months [95% CI] | 6-month PFS | CBR |
| --- | --- | --- | --- |
| All participants (n=86) | “4.6 [3.5, 6.5]” | “38%” | “40%” |
| Second or third line with or without chemotherapy (n=49) | “7.2 [3.7, 7.8]” | “54%” | “48%” |
| ESR1 mutation (n=36) | “5.6 [3.7, 7.8]” | “46%” | “52%” |
| ESR1 mutation, second or third line with or without chemotherapy (n=23) | “7.3 [5.0, NA]” | “62%” | “59%” |

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.3-7"></a>

###### Second- or third-line subset at 120 mg by ESR1 status (company announcement)

> “In a subset analysis of 49 patients that received palazestrant as a second- or third-line therapy with or without prior chemotherapy (the EMERALD trial eligibility criteria), the median PFS was 7.2 months and the CBR was 48% across all patients with a 6-month PFS rate of 54%. In patients with an ESR1 mutation, the median PFS was 7.3 months and CBR was 59% with a 6-month PFS rate of 62%. In ESR1 wild-type patients the median PFS was 5.5 months and the CBR was 38% with a 6-month PFS rate of 44%.”

Source: [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)

<a id="topic-3.1.2.8.3-8"></a>

###### ESR1 wild-type participants at 120 mg (company announcement)

> “In ESR1 wild-type patients, the median PFS was 3.5 months and the CBR was 32% with a 6-month PFS rate of 35%.”

Source: [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)

<a id="topic-3.1.2.8.3-9"></a>

###### Second- or third-line subset in the primary publication

> “In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall. Similarly, patients with cancers with ESR1 mutations had an extended PFS of 7.3 months and CBR of 59% in this subanalysis”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-10"></a>

###### Clinical benefit by on-treatment change in ESR1 mutations

> “In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-11"></a>

###### Dose escalation efficacy

> “Two confirmed partial responses were achieved as of the data cut-off date, each harboring an ESR1 mutation (1 each in the 60 mg and 120 mg cohorts; Figure 3); an additional tumor response occurring in the 30 mg cohort was unconfirmed, as progressive disease occurred at a follow-up visit”
> “In the cohorts within the anticipated RP2D range, the ORR was 18% and the CBR was 38%”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Dose escalation: dose-limiting toxicities

> “Palazestrant doses of up to 300 mg/day resulted in no DLTs, and the MTD was not reached. The majority of treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity in all dose-escalation cohorts of palazestrant”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-2"></a>

###### Adverse events occurring in at least 15% of participants, n (%)

| Event | 60 mg any grade (n = 30) | 60 mg grade 3 | 60 mg grade 4 | 120 mg any grade (n = 86) | 120 mg grade 3 | 120 mg grade 4 |
| --- | --- | --- | --- | --- | --- | --- |
| TEAE: nausea | “14 (46.7)” | “0” | “0” | “54 (62.8)” | “3 (3.5)” | “0” |
| TEAE: vomiting | “5 (16.7)” | “0” | “0” | “25 (29.1)” | “4 (4.7)” | “0” |
| TEAE: fatigue | “13 (43.3)” | “0” | “0” | “22 (25.6)” | “3 (3.5)” | “0” |
| TEAE: neutropenia | “2 (6.7)” | “0” | “0” | “21 (24.4)” | “3 (3.5)” | “6 (7.0)” |
| TEAE: headache | “7 (23.3)” | “0” | “0” | “17 (19.8)” | “0” | “0” |
| TEAE: constipation | “6 (20.0)” | “0” | “0” | “15 (17.4)” | “0” | “0” |
| TEAE: diarrhea | “6 (20.0)” | “1 (3.3)” | “0” | “12 (14.0)” | “0” | “0” |
| TRAE: nausea | “10 (33.3)” | “0” | “0” | “47 (54.7)” | “3 (3.5)” | “0” |
| TRAE: vomiting | “3 (10.0)” | “0” | “0” | “21 (24.4)” | “2 (2.3)” | “0” |
| TRAE: fatigue | “9 (30.0)” | “0” | “0” | “17 (19.8)” | “2 (2.3)” | “0” |
| TRAE: neutropenia | “0” | “0” | “0” | “18 (20.9)” | “3 (3.5)” | “5 (5.8)” |
| TRAE: headache | “3 (10.0)” | “0” | “0” | “13 (15.1)” | “0” | “0” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-3"></a>

###### Treatment-emergent adverse events at 120 mg/day

> “Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%). The majority of TEAEs were grade 1 or 2 in severity. Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]). Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-4"></a>

###### Treatment-related adverse events at 120 mg/day

> “The most common TRAEs of any grade were nausea (54.7%), vomiting (24.4%), fatigue (19.8%), neutropenia (20.9%), and headache (15.1%). Grade 3 treatment-related events occurred in 10 (11.6%) patients. Nausea and neutropenia (n = 3 each [3.5%]) and vomiting and fatigue (n = 2 each [2.3%]) were the most common grade 3 TRAEs. Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.”
> “In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-5"></a>

###### Aspartate aminotransferase increase at 120 mg (conference presentation, N=83)

| Event | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All, n (%) |
| --- | --- | --- | --- | --- | --- |
| AST increased | “10” | “2” | “1” | “0” | “13 (16)” |

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.5-6"></a>

###### Discontinuations due to adverse events and management of grade 4 neutropenia

> “Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue. Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia. In 3 patients, grade 4 neutropenia resolved following discontinuation of palazestrant. Grade 4 neutropenia occurred in 1 patient, concurrent with disease progression, and was assessed as not related to palazestrant.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-7"></a>

###### Timing of grade 4 neutropenia and monitoring in ongoing studies

> “While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors”
> “The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).”
> “All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-8"></a>

###### Prior CDK4/6 inhibitor exposure among participants with grade 4 neutropenia

> “Of the 86 patients treated, events of Grade 4 neutropenia were observed in six patients, occurring approximately 4–6 weeks into therapy.”
> “All six patients had prior exposure to CDK4/6 inhibitors.”

Source: [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)

<a id="topic-3.1.2.8.5-9"></a>

###### QTcF, bradycardia, and photopsia at 120 mg/day

> “There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.”
> “TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-10"></a>

###### Dose escalation: photopsia, bradycardia, and dose reductions

> “Two patients at 90 mg and 3 patients at 300 mg experienced photopsia (flashing lights). All events were grade 1 except for 1 event at 300 mg which was grade 2.”
> “Four patients experienced grade 1 asymptomatic bradycardia; 1 of these 4 was found to have a prior history of asymptomatic bradycardia. One patient was in the 120 mg cohort, 1 patient was in the 210 mg cohort, and 2 patients were in the 300 mg cohort. There was no interruption in OP-1250 dosing due to bradycardia.”
> “2 patients at 210 mg dose had reductions: 1 patient to 120 mg and 1 patient to 60 mg”
> “4 patients at 300 mg dose had reductions: 3 patients to 120 mg and 1 patient to 60 mg”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-3.1.2.8.5-11"></a>

###### Grade 3 treatment-related events at 60 and 120 mg in the interim analysis

> “3 patients had a grade 3 event assessed as related to study drug: anemia (60 mg), nausea (120 mg), and fatigue (120 mg)”
> “1 patient’s dose was reduced due to a related AE of grade 1 upper abdominal pain at 120 mg”

Source: [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)

Additional sources: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

OP-1250-001 was an open-label phase 1/2 study without a comparator arm, which the authors state limits interpretation of the safety profile and antitumor activity. Efficacy estimates come from dose cohorts of 30 participants at 60 mg/day and 86 at 120 mg/day, and only 6 participants were enrolled at 90 mg/day, during dose escalation. Response and CBR analyses used restricted populations: response required measurable disease and a postbaseline assessment (66 response-evaluable participants at 120 mg/day), and the CBR analysis excluded participants who discontinued without radiographic progression within 24 weeks. Two reports of the 120 mg cohort give different values: the peer-reviewed publication reports a CBR of 45.7% in 70 evaluable participants and a median PFS of 4.8 months, and the 2023 conference presentation reports a CBR of 40% (32/81) and a median PFS of 4.6 months. The study excluded primary endocrine resistance; fasted dosing, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule may have increased gastrointestinal events. The central nervous system metastases cohort is not included in the publication, and the association between ESR1 mutation reduction and CBR is based on 11 and 32 participants (CBR 73% [8/11] versus 25% [8/32]). All 116 participants treated at 60 or 120 mg/day were women, 33.6% had received prior chemotherapy, and 8.6% had received 5 or more prior lines of therapy in the advanced setting.

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/); [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.9-2"></a>

###### Open-label design without a comparator arm

> “Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-3"></a>

###### Limited data at 90 mg/day

> “Limited data were available for patients treated with 90 mg palazestrant, as only 6 patients were enrolled during dose escalation.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-4"></a>

###### Population excluded primary endocrine resistance

> “The study did not include patients with primary endocrine resistance.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-5"></a>

###### Study conditions that may have increased gastrointestinal events

> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-6"></a>

###### Cross-trial comparisons and small biomarker subgroups

> “While between-study comparisons should always be made with caution because of variations in patient populations, equivalent dosing levels, and study designs”
> “While the correlation between reductions in ESR1 mutations and CBR is encouraging based on a small number of patients, these findings should be further explored in larger trials.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-7"></a>

###### Central nervous system cohort not reported

> “CNS metastases (exploratory cohort, not included in this report)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="heading-3.1.3"></a>

#### 3.1.3 OP-1250-003

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Dose escalation and dose expansion objectives

> “determine the RP2D (Recommended Phase 2 Dose) for each treatment group”
> “provide an exploratory estimate of anti-tumor activity of the combinations”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.1-2"></a>

###### Original objective for the ribociclib and alpelisib groups

> “To evaluate the safety, pharmacokinetics, and antitumor activity of daily, oral administration of OP-1250 plus ribociclib or alpelisib in patients with advanced or metastatic HR+/HER2− breast cancer”

Source: [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)

<a id="topic-3.1.3.1-3"></a>

###### Atirmociclib group objective

> “The companies will evaluate in a Phase 1b/2 study the safety and combinability of palazestrant plus atirmociclib, Pfizer’s investigational, highly selective-CDK4 inhibitor, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.”

Source: [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry dates and planned enrollment

| Item | Value |
| --- | --- |
| Study start (actual) | “2022-08-31” |
| Primary completion (estimated) | “2027-12-31” |
| Study completion (estimated) | “2028-01-31” |
| Enrollment (estimated) | “190” |

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.2-2"></a>

###### Planned study sites

> “Enrollment is ongoing and expected at approximately 20 sites in the United States and Australia.”

Source: [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)

<a id="topic-3.1.3.2-3"></a>

###### Ribociclib group: most recent data cutoff and presentation

> “78 patients were enrolled in the dose-expansion and dose-escalation cohorts as of July 8, 2025.”
> “Poster presented at: European Society for Medical Oncology Congress; October 17-21, 2025; Berlin, Germany.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.2-4"></a>

###### Everolimus group initiation

> “In the third quarter of 2024, we initiated evaluation of palazestrant in combination with everolimus in a Phase 1b/2 clinical study.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-3.1.3.2-5"></a>

###### Atirmociclib group initiation and enrollment

> “Initiated the Phase 1b/2 study evaluating palazestrant in combination with atirmociclib in estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer in collaboration with Pfizer.”

Source: [Olema Oncology fourth quarter and full year 2025 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-fourth-quarter-and-full-year-2025)

<a id="topic-3.1.3.2-6"></a>

###### Atirmociclib group enrollment completed

> “Completed enrollment in the Phase 1b/2 study of palazestrant in combination with atirmociclib in ER+/HER2- MBC.”

Source: [Olema Oncology second quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-second-quarter-2026-financial-and)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase 1b open-label design with four treatment groups

> “This is a Phase 1b open-label, 2-part study in 4 treatment groups.”
> “Treatment Group 4: Palazestrant in combination with atirmociclib”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.3-2"></a>

###### Dose escalation followed by dose expansion

> “The OP-1250-003 study comprises a dose-escalation phase, followed by a dose-expansion phase. The study investigates palazestrant in combination with ribociclib, alpelisib, or everolimus.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.3-3"></a>

###### Dose-escalation method

> “3 + 3 design”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.3-4"></a>

###### Alternate dose level in the ribociclib group

> “An additional group of palazestrant at an alternate dose level in combination with ribociclib (Treatment Group 1b) will be explored to optimize the RP2D of palazestrant.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.3-5"></a>

###### Expansion of the ribociclib group

> “The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.”

Source: [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Ribociclib group: key eligibility criteria

> “Women or men with ER+, HER2− advanced or metastatic breast cancer.”
> “Up to 2 prior endocrine therapies ± a CDK4/6i for locally advanced or metastatic disease; up to 1 prior line of chemotherapy for advanced or metastatic breast cancer was allowed.”
> “Evaluable disease (measurable by RECIST v1.1 or bone only).”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.4-2"></a>

###### Cardiac screening criteria

> “Screening QTcF <450 ms, resting heart rate 50-90 beats/min”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.4-3"></a>

###### Prior therapy limits by treatment group in the current registry record

> “Has received no more than 1 prior hormonal regimen (Treatment Group 1).”
> “Prior hormonal regimens in combination with CDK4/6 inhibitors are allowed in all treatment groups.”
> “For subjects in Treatment Group 4, no prior chemotherapy for metastatic breast cancer is allowed.”
> “Have received prior treatment with approved or investigational PI3K inhibitor (Treatment Group 2) or mTOR inhibitor (Treatment Group 3).”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.4-4"></a>

###### Alpelisib group and central nervous system criteria

> “Presence of PIK3CA mutation”
> “No prior treatment with a PI3K inhibitor (OP-1250 plus alpelisib group)”
> “Patients with stable or treated brain metastases are eligible”

Source: [Borges et al. (2023a)](https://olema.com/wp-content/uploads/2023/06/Olema_ASCO_OP1250-003-TIP_Poster_6-4-23.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Ribociclib group: dose escalation regimen

> “palazestrant at 30, 60, and 120 mg once daily plus ribociclib 600 mg once daily on days 1–21 of each 28-day treatment cycle”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.5-2"></a>

###### Ribociclib group: doses in the most recent analysis

> “Here we present the data for 72 patients: 56 patients received 120 mg QD palazestrant and 16 patients received 90 mg QD palazestrant, all with 600 mg of ribociclib.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.5-3"></a>

###### Alpelisib, everolimus, and atirmociclib group regimens

> “with 300 mg or 250 mg of alpelisib administered PO daily (Treatment Group 2) or with everolimus 10 mg administered PO daily (Treatment Group 3)”
> “Part 1, for Treatment Group 4, will evaluate the safety and pharmacokinetics of OP-1250 at 60 mg or 90 mg doses administered orally (PO) QD in combination with atirmociclib 300 mg PO twice a day (BID).”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Dose-limiting Toxicities as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Ribociclib group: primary and secondary endpoints by study part

| Part | Primary endpoints | Secondary endpoints |
| --- | --- | --- |
| Dose escalation | “DLTs, MTD, and/or RP2D of palazestrant when administered in combination with ribociclib, incidence and severity of adverse events, PK” | “ORR (CR + PR), CBR (CR + PR + SD ≥24 weeks), DOR” |
| Dose expansion | “Incidence and severity of adverse events, PK” | “ORR (CR + PR), CBR (CR + PR + SD ≥24 weeks), DOR, time to progression, PFS” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.6.1-2"></a>

###### Dose-limiting toxicity assessment window

> “The incidence of DLTs will be assessed in the Dose Escalation part (Part 1) of the study.”
> “The first 28 days of treatment”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="topic-3.1.3.6.1-3"></a>

###### Dose-limiting toxicity observation period in the ribociclib group

> “the DLT observation period was at least 4 weeks”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.6.1-4"></a>

###### Response assessment

> “as assessed by the investigator using RECIST v1.1.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned ribociclib group size after the 2023 amendment

> “to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients.”

Source: [Olema Oncology Novartis collaboration expansion announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-expansion-collaboration-agreement)

<a id="topic-3.1.3.7.1-2"></a>

###### Ribociclib group: enrolled and analyzed participants, July 2025 data cutoff

> “78 patients were enrolled in the dose-expansion and dose-escalation cohorts as of July 8, 2025.”
> “Here we present the data for 72 patients: 56 patients received 120 mg QD palazestrant and 16 patients received 90 mg QD palazestrant, all with 600 mg of ribociclib.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.1-3"></a>

###### Ribociclib group: participants by cohort, July 2025 data cutoff

| Cohort | Participants |
| --- | --- |
| Dose escalation, palazestrant 30 mg | “30 mg (n=3)” |
| Dose escalation, palazestrant 60 mg | “60 mg (n=3)” |
| Dose escalation, palazestrant 120 mg | “120 mg (n=3)” |
| Dose expansion, palazestrant 90 mg | “90 mg (n=16)” |
| Dose expansion, palazestrant 120 mg | “120 mg (n=53)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.1-4"></a>

###### Ribociclib group: March 2024 interim analysis population

> “60 patients were enrolled as of March 13, 2024; 50 patients who had 4 weeks or more of follow-up were included in this analysis.”

Source: [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)

<a id="topic-3.1.3.7.1-5"></a>

###### Ribociclib group: September 2024 interim analysis population

> “62 patients were enrolled as of September 25, 2024.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Response-evaluable population

> “34% (15/44) objective response rate (ORR) among response-evaluable patients with measurable disease.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.2-2"></a>

###### Follow-up calculation and pharmacokinetic sampling

> “Follow-up was calculated from first dose date to data cutoff date regardless of disease progression status.”
> “Rich pharmacokinetic samples collected at cycle 2 day 15.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.7.2-3"></a>

###### Clinical benefit rate definition

> “CBR is the proportion of patients who remained on treatment through at least 24 weeks with a confirmed complete response or partial response, or stable disease.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.7.2-4"></a>

###### Central ESR1 mutation testing

> “ESR1 mutations in ctDNA at baseline were determined centrally using SafeSEQ Breast Cancer Panel (Sysmex Inostics, Baltimore, MD). Three samples were not evaluable.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Ribociclib group: treatment status, July 2025 data cutoff

> “42% (30/72) patients remain on treatment; efficacy maturing.”
> “The longest duration of treatment in the 120 mg cohort is 103 weeks and ongoing.”
> “The most common reason for treatment discontinuation was disease progression.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.1-2"></a>

###### Ribociclib group: discontinuations due to adverse events

> “Three patients discontinued both treatments due to a TEAE (depression Gr 3, n=1; neutropenia Gr 4, n=1; vomiting and febrile neutropenia both Gr 3, n=1) and 3 patients discontinued ribociclib only (neutropenia Gr 4, n=2; fatigue Gr 3, n=1).”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Ribociclib group: baseline demographics and disease characteristics, July 2025 data cutoff

| Characteristic | Palazestrant 90 mg (n=16) | Palazestrant 120 mg (n=56) | Total (N=72) |
| --- | --- | --- | --- |
| Median age, years (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |
| Female sex, n (%) | “16 (100%)” | “56 (100%)” | “72 (100%)” |
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |
| ECOG performance status 0, n (%) | “10 (63%)” | “34 (61%)” | “44 (61%)” |
| ECOG performance status 1, n (%) | “6 (38%)” | “22 (39%)” | “28 (39%)” |
| Measurable disease at baseline, n (%) | “12 (75%)” | “37 (66%)” | “49 (68%)” |
| Visceral disease, n (%) | “6 (38%)” | “33 (59%)” | “39 (54%)” |
| No prior line of therapy in the advanced setting, n (%) | “10 (63%)” | “14 (25%)” | “24 (33%)” |
| One prior line of therapy in the advanced setting, n (%) | “5 (31%)” | “26 (46%)” | “31 (43%)” |
| Two prior lines of therapy in the advanced setting, n (%) | “1 (6.3%)” | “12 (21%)” | “13 (18%)” |
| Three prior lines of therapy in the advanced setting, n (%) | “0” | “4 (7%)” | “4 (6%)” |
| Prior CDK4/6 inhibitor in the advanced setting, n (%) | “5 (31%)” | “40 (71%)” | “45 (63%)” |
| Prior aromatase inhibitor in the advanced setting, n (%) | “5 (31%)” | “27 (48%)” | “32 (44%)” |
| Prior fulvestrant in the advanced setting, n (%) | “1 (6%)” | “22 (39%)” | “23 (32%)” |
| Prior chemotherapy in the advanced setting, n (%) | “1 (6.3%)” | “10 (18%)” | “11 (15%)” |
| ESR1 mutation at baseline | “1/15 (7%)” | “14/54 (26%)” | “15/69 (22%)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.2-2"></a>

###### Ribociclib group: prior CDK4/6 inhibitor exposure and ESR1 mutation status

> “45 (63%) patients (40 patients at 120 mg; 5 patients at 90 mg) received prior CDK4/6i with endocrine therapy for advanced disease.”
> “36 (50%) received 1 prior CDK4/6i (palbociclib, n=23; abemaciclib, n=8; ribociclib, n=5).”
> “At baseline, 22% (15/69) of all patients had tumors with ESR1 mutations; 33% (15/45) of patients with one prior line of therapy in the advanced setting (2L/3L+) had tumors with ESR1 mutations.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Ribociclib group: progression-free survival in the 120 mg cohort, including participants with prior CDK4/6 inhibitor treatment

> “For patients in the palazestrant 120 mg dose cohort, median PFS was 15.5 mos for all patients, 12.2 mos with prior CDK4/6i, 9.2 mos for ESR1-wt with prior CDK4/6i, and 13.8 mos for ESR1-mut with prior CDK4/6i-treated ABC.”
> “Among all patients, median follow-up was 19.1 mos, 19.8 mos in patients with prior CDK4/6i, 20 mos in patients with ESR1-wt disease with prior CDK4/6i, and 18.0 mos for patients with ESR1-mut disease with prior CDK4/6i treatment.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-2"></a>

###### Ribociclib group: maturity of progression-free survival in the 120 mg cohort

> “In the 120 mg palazestrant dose cohort, with a median follow-up of more than 19 months, median PFS are mature.”

Source: [Olema Oncology ESMO 2025 ribociclib results announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-data-phase-1b2-trial-palazestrant)

<a id="topic-3.1.3.8.3-3"></a>

###### Ribociclib group: progression-free survival in the 90 mg cohort

> “In the 90 mg palazestrant dose cohort, the median follow-up was 10.8 months. The median PFS was not reached.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-4"></a>

###### Ribociclib group: objective response rate, July 2025 data cutoff

| Population | Objective response rate (n/n) |
| --- | --- |
| 90 mg cohort (n=12) | “42% (5/12)” |
| 120 mg cohort (n=32) | “31% (10/32)” |
| Prior CDK4/6i, 120 mg cohort (n=23) | “26% (6/23)” |
| All (n=44) | “34% (15/44)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-5"></a>

###### Ribociclib group: responses after prior CDK4/6 inhibitor treatment

> “26% (6/23) ORR among patients with prior CDK4/6i, including 6 confirmed partial responses (cPRs) in the 120 mg cohort.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-6"></a>

###### Ribociclib group: 6-month progression-free survival and clinical benefit rate, September 2024 data cutoff

> “With a median follow-up of 10 months, median PFS was not reached.”
> “6-month PFS rate was 72% in all patients, 67% with prior CDK4/6i, 70% with ESR1-wt and 81% with ESR1-mut mBC.”
> “CBR was 76% in all patients, 71% with prior CDK4/6i, 74% with ESR1-wt and 81% with ESR1-mut mBC.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.8.3-7"></a>

###### Ribociclib group: clinical benefit rate after prior CDK4/6 inhibitor treatment, November 2024 data cutoff

> “In patients with prior CDK4/6i treatment, the CBR was 71% (25/35), 81% (13/16) in patients with ESR1 mutations, and 65% (11/17) in ESR1 wild-type patients.”

Source: [Olema Oncology SABCS 2024 announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-presents-updated-clinical-results-palazestrant)

<a id="topic-3.1.3.8.3-8"></a>

###### Ribociclib group: pharmacokinetic interaction results

> “Palazestrant had no clinically meaningful effect on ribociclib 600 mg steady-state exposure when compared with published concentrations for single-agent ribociclib.”
> “Ribociclib had no clinically meaningful effect on palazestrant exposure”
> “Steady-state plasma concentrations at both 90 mg and 120 mg doses exceeded the predicted efficacious threshold”
> “There was no clinically significant difference in exposure between 90 mg and 120 mg doses.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.3-9"></a>

###### Ribociclib group: steady-state ribociclib 600 mg exposure, October 2023 data cutoff

| Parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
| --- | --- | --- |
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), Median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.8.3-10"></a>

###### Ribociclib group: CYP3A4 interaction mechanism

> “Ribociclib is metabolized mainly by CYP3A4. Palazestrant is not a CYP3A4 inhibitor or inducer.”
> “Ribociclib is a strong inhibitor of CYP3A4. While palazestrant is metabolized by CYP3A4, it is not sensitive to CYP3A4 inhibition.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-3.1.3.8.3-11"></a>

###### Everolimus and atirmociclib groups: first data scheduled for December 2026

> “Title: Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer”
> “Title: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer”

Source: [Olema Oncology SABCS 2026 presentations announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-present-combination-data-palazestrant-and-op-3136)

<a id="topic-3.1.3.8.3-12"></a>

###### Atirmociclib group: data timing

> “The Phase 1b/2 study investigating palazestrant in combination with atirmociclib has completed enrollment and we expect to present initial data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

Additional sources: [Lin et al. (2025a)](https://www.annalsofoncology.org/article/S0923-7534(25)01845-9/fulltext)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Ribociclib group: dose-limiting toxicities and overall severity

> “No dose-limiting toxicities were observed during the dose-escalation phase, and the maximum tolerated dose was not reached.”
> “The majority of related TEAEs were grade 1 and 2.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.5-2"></a>

###### Ribociclib group: related treatment-emergent adverse events in at least 25% of participants, n (%)

| Event | 120 mg (n=56), all grades | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg (n=16), all grades | 90 mg, grade 3 | 90 mg, grade 4 |
| --- | --- | --- | --- | --- | --- | --- |
| Neutropenia (combined term) | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| White blood cell decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Anemia | “22 (39%)” | “2 (4%)” | “0” | “5 (31%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| Lymphocyte decrease | “16 (29%)” | “3 (5%)” | “1 (2%)” | “3 (19%)” | “0” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |
| Constipation | “15 (27%)” | “0” | “0” | “3 (19%)” | “0” | “0” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.5-3"></a>

###### Ribociclib group: dose reductions and grade 5 events

> “2 patients had a dose reduction of palazestrant only; 1 due to nausea and 1 due to neutropenia”
> “8 patients had a dose reduction of both treatments; 23 patients had a dose reduction of ribociclib. The most common cause for dose reduction was neutropenia.”
> “Two patients experienced Gr 5 AEs: organ failure, and depressed level of consciousness; none of which were related to palazestrant.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.8.5-4"></a>

###### Ribociclib group: reasons for ribociclib dose reduction, March 2024 data cutoff

> “10 patients had dose reduction of ribociclib only. Reasons for dose reduction were QTcF prolongation (n=4; Grade 3, n=2; Grade 2, n=1; Grade 1, n=1), neutropenia (n=4; Grade 3, n=3; Grade 2, n=1) or fatigue (n=2; Grade 2).”

Source: [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf)

<a id="topic-3.1.3.8.5-5"></a>

###### Ribociclib group: QTcF in the dose-escalation analysis

> “No QTcF values of >500 ms were observed at any time point.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

OP-1250-003 is an open-label phase 1b, 2-part study in 4 treatment groups, and the 2025 presentation cautions that its comparison aggregates results across independent studies and carries the risks inherent in cross-trial comparisons. The ribociclib group population differs from this indication: 24 of 72 participants (33%) had no prior line of therapy in the advanced setting, and 45 (63%) had received a prior CDK4/6 inhibitor. Cohorts include 16 participants at palazestrant 90 mg and 56 at 120 mg, and response rates are based on 12 and 32 response-evaluable participants, respectively. The presentation describes efficacy as “maturing”: 30 of 72 participants (42%) remained on treatment at the July 8, 2025 cutoff, and median PFS in the 90 mg cohort was not reached at a median follow-up of 10.8 months. Responses were assessed by the investigator, and the analysis presented 72 of 78 enrolled participants. Interim results were reported at successive cutoffs (March 13, 2024; September 25, 2024; and July 8, 2025) with different analysis populations.

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906); [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97); [Borges et al. (2024a)](https://olema.com/wp-content/uploads/2024/05/Olema_Final_ESMO-Breast-2024_OP-1250-003_5-15-24.pdf); [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-3.1.3.9-2"></a>

###### Cross-trial comparison with MONALEESA-2

> “This analysis is the aggregation of results across independent studies. There are risks inherent in conducting cross-trial comparisons and results should be interpreted with caution.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-3.1.3.9-3"></a>

###### Open-label design without a comparator group

> “This is a Phase 1b open-label, 2-part study in 4 treatment groups.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

<a id="heading-3.1.4"></a>

#### 3.1.4 OP-1250-002

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Study purpose

> “Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).”

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.1-2"></a>

###### Primary objectives by study part

> “Primary objectives: Determine MTD and/or RP2D, safety and tolerability, and PK of palazestrant in combination with palbociclib”
> “Primary objectives: Safety and tolerability and PK of palazestrant at RP2D in combination with palbociclib”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry dates and enrollment

| Item | Value |
| --- | --- |
| Study start (actual) | “2021-12-10” |
| Primary completion (estimated) | “2026-03” |
| Enrollment (actual) | “60” |

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.2-2"></a>

###### Enrollment period, sites, and data cutoff

> “46 patients were enrolled at 8 sites between January 2022 and August 2023. Data cutoff date for this analysis was September 15, 2023.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.2-3"></a>

###### Palbociclib supply agreement

> “The companies’ previous agreement was established in November 2020 to evaluate palazestrant in combination with palbociclib (IBRANCE®) in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer.”

Source: [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label dose escalation and expansion

> “This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib”

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.3-2"></a>

###### Two-part structure

> “The OP-1250-002 study comprises two parts: a dose-escalation phase followed by a dose-expansion phase.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key eligibility criteria

> “Women (regardless of menopausal status) or men with HR+/HER2– advanced or metastatic breast cancer”
> “Zero or one prior endocrine therapy ± a CDK4/6 inhibitor for locally advanced or metastatic disease”
> “one prior line of chemotherapy for advanced or metastatic breast cancer was allowed”
> “Evaluable disease (measurable or non-measurable by RECIST 1.1)”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.4-2"></a>

###### Registry exclusion criteria

> “Significant cardiovascular disease”
> “Significant ECG abnormalities”
> “History of pulmonary embolism or high risk of thrombosis”

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose escalation and dose expansion regimens

> “Patients received 30, 60, 90, or 120 mg palazestrant QD plus 125 mg palbociclib PO QD on days 1–21 of each 28-day treatment cycle.”
> “Dose-expansion (ongoing) patients receive 120 mg palazestrant plus 125 mg palbociclib QD.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Dose-limiting Toxicities as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registry primary outcomes

| Primary outcome | Time frame |
| --- | --- |
| “Incidence of Dose Limiting Toxicities” | “From Cycle 1 Day 1 through C1 Day 28” |
| “Characterization and Incidence in Adverse Events and Serious Adverse Events” | “From initial inform consent date through 30 days post last dose” |
| “Plasma levels of OP-1250 and Palbociclib” | “Up to 9 months” |

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.6.1-2"></a>

###### Secondary objectives

> “Secondary objectives: ORR (CR + PR), CBR (CR + PR + SD ≥24 weeks)”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Enrolled and planned participants, September 2023 data cutoff

> “Thirty-four patients were enrolled in this part; approximately 45 patients are planned for enrollment in the dose-expansion phase.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants by palazestrant dose, September 2023 data cutoff

| Palazestrant dose | Participants |
| --- | --- |
| 30 mg | “30 mg (n=3)” |
| 60 mg | “60 mg (n=3)” |
| 90 mg | “90 mg (n=3)” |
| 120 mg | “120 mg (n=37)” |
| Total | “Total (N=46)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.7.1-3"></a>

###### Earlier interim analysis population

> “29 patients were enrolled as of March 8, 2023”

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Clinical benefit rate and ESR1 analysis populations

> “Clinical benefit rate was 46% (12/26 patients) in all patients and 60% (6/10) in patients with ESR1 mutation in ctDNA at baseline.”
> “ctDNA from 37 patients was available at the time of data cutoff for ESR1 mutation evaluation.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Pharmacokinetic sampling schedule

> “Plasma samples for OP-1250 assessment were collected on C1 day (D) 1 (C1D1), C1D2/D8/D15, C2D15/D16, C3D1/D15, C5D1, C7D1, and C9D1. For palbociclib, they were collected on C1D15, C2D15, and C3D15.”

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Treatment status and reasons for discontinuation, September 2023 data cutoff

| Status | Total (N=46), n (%) |
| --- | --- |
| Treatment ongoing | “22 (48)” |
| Treatment discontinued | “24 (52)” |
| Discontinued for disease progression | “18 (39)” |
| Discontinued for physician decision | “3 (7)” |
| Discontinued for patient decision | “2 (4)” |
| Discontinued for adverse event | “1 (2)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline demographics and disease characteristics, September 2023 data cutoff

| Characteristic | Total (N=46), n (%) |
| --- | --- |
| Median age, years (range) | “63.5 (30–77)” |
| Female sex | “45 (98)” |
| Premenopausal | “4 (9)” |
| ECOG performance status 0 | “31 (67)” |
| ECOG performance status 1 | “15 (33)” |
| Measurable disease | “36 (78)” |
| Visceral disease | “20 (44)” |
| One prior line of therapy for advanced disease | “34 (74)” |
| One prior line of endocrine therapy for advanced disease | “40 (87)” |
| Prior CDK4/6 inhibitor for advanced disease | “33 (72)” |
| Prior aromatase inhibitor for advanced disease | “35 (76)” |
| Prior fulvestrant for advanced disease | “5 (11)” |
| Prior chemotherapy for advanced disease | “10 (22)” |
| ESR1 mutation at baseline (ctDNA) | “16/37 (43)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.2-2"></a>

###### Prior CDK4/6 inhibitor exposure

> “33 (72%) patients received prior treatment with CDK4/6 inhibitors for advanced disease (palbociclib, n=22; ribociclib, n=10; both palbociclib and ribociclib, n=1).”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Responses, clinical benefit, and treatment duration, September 2023 data cutoff

> “Partial responses were observed in seven patients. (2 cPR; 5uPR)”
> “Clinical benefit rate was 46% (12/26 patients) in all patients and 60% (6/10) in patients with ESR1 mutation in ctDNA at baseline.”
> “53% of patients had any reduction in target lesion size.”
> “Longest duration of treatment is 76 weeks and ongoing.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.3-2"></a>

###### Clinical benefit rate without prior CDK4/6 inhibitor treatment

> “In patients naïve to prior CDK4/6 inhibitor treatment, the CBR was 71%.”

Source: [Olema Oncology SABCS 2023 combination results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-demonstrates-attractive)

<a id="topic-3.1.4.8.3-3"></a>

###### Pharmacokinetic interaction results

> “There was no effect of palazestrant (30-120 mg) on palbociclib 125 mg exposure parameters.”
> “Cmax ratios of combination therapy to monotherapy ranged from 96% to 107%.”
> “Palbociclib 125 mg did not affect palazestrant (30-120 mg) exposure parameters.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.3-4"></a>

###### Palazestrant steady-state pharmacokinetics with palbociclib 125 mg, March 2023 data cutoff

| Palazestrant dose | Cmin (ng/mL) | Cmax (ng/mL) | Cavg (ng/mL) | Tmax (h) | AUC0–24 (ng*h/mL) |
| --- | --- | --- | --- | --- | --- |
| “30 mg (n=2)” | “61.2 (38%)” | “136 (49%)” | “94.7 (13%)” | “2.0 (2.0–2.0)” | “2270 (13%)” |
| “60 mg (n=3)” | “186 (52%)” | “337 (24%)” | “253 (43%)” | “2.0 (2.0–2.0)” | “6070 (43%)” |
| “90 mg (n=3)” | “199 (55%)” | “549 (63%)” | “341 (49%)” | “2.0 (2.0–4.0)” | “8180 (49%)” |
| “120 mg (n=12)” | “313 (43%)” | “573 (43%)” | “429 (39%)” | “4.0 (2.0–6.0)” | “10300 (39%)” |

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

Additional sources: [Chan et al. (2024)](https://aacrjournals.org/cancerres/article/84/9_Supplement/PS15-04/744001/Abstract-PS15-04-A-Phase-1b-2-study-of)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Dose-limiting toxicities and overall severity

> “No DLTs were observed during the dose-escalation part of the study.”
> “Most treatment-emergent adverse events (TEAEs) were grade 1 or 2.”
> “There were no dose-related increases in incidence or severity of TEAEs.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.5-2"></a>

###### Treatment-emergent adverse events in at least 20% of participants, total population (N=46), n (%)

| Event | All grades | Grade 3 | Grade 4 |
| --- | --- | --- | --- |
| Neutropenia (combined term) | “40 (87)” | “28 (61)” | “5 (11)” |
| Nausea | “26 (57)” | “0” | “0” |
| Vomiting | “17 (37)” | “0” | “0” |
| Anemia | “12 (26)” | “1 (2)” | “0” |
| Diarrhea | “11 (24)” | “0” | “0” |
| Constipation | “10 (22)” | “1 (2)” | “0” |
| Fatigue | “10 (22)” | “1 (2)” | “0” |
| Thrombocytopenia | “10 (22)” | “0” | “0” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.5-3"></a>

###### Dose reductions and discontinuations

> “One patient discontinued both drugs due to an AE of nausea concurrent with documented disease progression.”
> “No patients had dose reduction of palazestrant for neutropenia. Eleven patients had dose reduction of palbociclib for neutropenia.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.5-4"></a>

###### Fatal events in the earlier interim analysis

> “There were no treatment-related fatal events”

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

OP-1250-002 is an open-label phase 1b dose-escalation and dose-expansion study. Eligibility allowed zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease, which admits participants outside previously treated disease; 33 of 46 participants (72%) had received a prior CDK4/6 inhibitor. The CBR is based on 26 evaluable participants overall and 10 with ESR1 mutations, and circulating tumor DNA for ESR1 testing was available for 37 participants. The reported results have a data cutoff of September 15, 2023, at which 22 participants (48%) remained on treatment and the data were described as maturing. The registry lists an actual enrollment of 60 participants, whereas the reported analysis includes 46.

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf); [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.9-2"></a>

###### Immature efficacy data and incomplete ESR1 testing

> “Data are maturing; 22 patients (48%) remain on treatment.”
> “ctDNA from 37 patients was available at the time of data cutoff for ESR1 mutation evaluation.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 OPERA-02

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Primary comparison

> “This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registry dates and planned enrollment

| Item | Value |
| --- | --- |
| Study start (actual) | “2025-11-03” |
| Primary completion (estimated) | “2028-12” |
| Study completion (estimated) | “2032-01” |

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.2-2"></a>

###### Enrollment start

> “Enrollment began in November 2025.”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.2-3"></a>

###### Participating countries

> “Australia Austria Belgium Brazil Canada Chile Czechia France Germany Greece Hong Kong Hungary Israel Italy Malaysia Mexico The Netherlands The Philippines Poland Portugal Romania South Korea Spain Taiwan Thailand UK USA”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.2-4"></a>

###### Enrollment status

> “Enrollment is accelerating, investigator interest is strong, and patients with frontline disease continue to require better therapeutic options.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-3.1.5.2-5"></a>

###### Anticipated top-line data

> “We anticipate top-line data in 2028 and, if successful, anticipate potential FDA approval and commercial launch in the frontline MBC setting in the United States in 2029.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized, double-blind, active-controlled design

> “This is an international, multicenter, randomized, double-blind, active-controlled, phase 3 clinical trial.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.3-2"></a>

###### Stratification factors and randomization ratio

> “Menopausal status: post vs pre- or peri-/male”
> “Visceral metastasis: yes vs no”
> “De novo metastatic disease vs recurrent disease after adjuvant ET”
> “Geographical region: US, Canada and Australia vs Europe vs Other”
> “1:1”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Key inclusion criteria

> “Newly diagnosed advanced breast cancer or disease recurrence occurring after 12 months of completing adjuvant endocrine therapy with or without CDK4/6 inhibitor”
> “Evaluable disease (measurable disease or evaluable bone disease)”
> “Female participants can be pre-, peri-, or post-menopausal”
> “Male and pre- or peri-menopausal female participants must be willing to take a gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) agonist”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.4-2"></a>

###### Key exclusion criteria

> “Disease recurrence during or within 12 months of completing adjuvant endocrine therapy”
> “Prior treatment with a SERD or any investigational endocrine therapy”
> “Active or symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.4-3"></a>

###### Prior endocrine therapy exclusions in the registry record

> “Previously received treatment with fulvestrant, elacestrant or an investigational endocrine therapy in any setting.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Investigational and control regimens

> “Palazestrant 90 mg QD and letrozole-matching placebo QD on days 1-28; ribociclib 600 mg QD on days 1-21.”
> “Letrozole 2.5 mg QD and palazestrant-matching placebo QD on days 1-28; ribociclib 600 mg QD on days 1-21.”

Source: [Tolaney et al. (2025)](https://ir.olema.com/static-files/e5b62d98-7b5b-46fa-9d9a-bbc378f6749b)

<a id="topic-3.1.5.5-2"></a>

###### Selection of the 90 mg dose

> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-3.1.5.5-3"></a>

###### Ribociclib supply

> “Under the terms of the agreement, Novartis will provide Olema with ribociclib drug supply for the planned, Olema-sponsored, Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer.”

Source: [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Investigator-assessed Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary, key secondary, and other secondary endpoints

| Endpoint role | Endpoint |
| --- | --- |
| Primary endpoint | “PFS, as assessed by local investigator” |
| Key secondary endpoint | “OS” |
| Other secondary endpoint | “PFS (per BIRC)” |
| Other secondary endpoint | “ORR, CBR, and DOR (per local investigator and BIRC)” |
| Other secondary endpoint | “PFS2” |
| Other secondary endpoint | “Safety and tolerability” |
| Other secondary endpoint | “PK” |
| Other secondary endpoint | “Patient-reported outcomes” |

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.6.1-2"></a>

###### Registry definition of the primary outcome

> “To compare PFS, based on a local investigator assessment, between investigational (palazestrant with ribociclib + letrozole-matching placebo) and control (letrozole with ribociclib + palazestrant-matching placebo) arms.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.6.1-3"></a>

###### Patient-reported outcomes as a secondary endpoint

> “To evaluate the change from baseline in health-related PROs assessed using standardized instruments that are widely used in (breast) cancer clinical trials”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.6.1-4"></a>

###### Regulatory rationale for progression-free survival

> “PFS can reflect tumor growth”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned randomization

> “Approximately 1,000 participants will be randomized in a 1:1 ratio to one of the two study arms.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.7.1-2"></a>

###### Planned participants per arm

> “n ≈ 500”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

No results from OPERA-02 have been reported; primary completion is estimated for December 2028, and top-line data are anticipated in 2028. The trial enrolls participants with no prior systemic therapy for advanced breast cancer and tests palazestrant in combination with ribociclib, so its population and regimen are outside this indication of previously treated disease and palazestrant monotherapy. The primary endpoint is investigator-assessed PFS, with PFS by blinded independent central review as a secondary endpoint. Participants previously treated with fulvestrant, elacestrant, or an investigational endocrine therapy in any setting are excluded.

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767); [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-3.1.5.9-2"></a>

###### First-line population outside the previously treated indication

> “No prior systemic therapy for ABC”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
